RNA Interference and Its Key Targets for Spinal Cord Injury Therapy: What Is Known So Far?

Area of Science:

• Neuroscience
• Molecular Biology
• Biotechnology

Background:

• Spinal cord injury (SCI) causes significant motor and sensory deficits with limited effective treatments.
• RNA interference (RNAi) is a gene silencing mechanism with therapeutic potential for neurological disorders.

Purpose of the Study:

• To review the pathological processes in SCI and the potential of RNAi as a therapeutic strategy.
• To highlight RNAi's ability to target both protein-coding and non-coding RNAs involved in SCI pathology.

Main Methods:

• Overview of SCI pathology, including primary injury and secondary cascades (inflammation, excitotoxicity, oxidative stress, cell death).
• Exploration of RNAi mechanisms and novel tools like CRISPR-Cas13 for gene silencing.
• Discussion of challenges and future directions for RNAi-based SCI therapy.

Main Results:

• RNAi can selectively silence genes contributing to SCI pathology, promoting neuroprotection and functional recovery.
• Non-coding RNAs (ncRNAs) are identified as viable targets for RNAi in SCI.
• CRISPR-Cas13 technology offers new avenues for RNAi-based SCI therapeutics.

Conclusions:

• RNAi is a promising, yet underdeveloped, therapeutic approach for SCI.
• Delivery methods, long-term efficacy, and cell-specific targeting require further investigation.
• Combination therapies (e.g., RNAi with cell- or biomaterial-based approaches) may improve outcomes.